ME Therapeutics(AXSM)

Focus: ME Therapeutics is a publicly traded biotech (AXSM) founded in 2023, focused on immunooncology drugs targeting novel myeloid cell targets. The company operates with $315M in cash and is in early-stage development with a diverse but unfocused pipeline.

Oncology

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Total Funding

$1B

Open Jobs

About ME Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow ME Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$271M

Pipeline & Clinical Trials

The Myelin Disorders Biorepository Project

Leukodystrophy

N/A

Mindfulness and Meditation-Based Relapse Prevention Program

Substance Use Disorders

N/A

Clinical Trials (1)

Help build intelligence for ME Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status provides liquidity and career stability relative to pre-revenue biotech peers.
36% R&D intensity and $98M annual R&D spend (FY2025) signal meaningful investment in drug discovery.
Recently raised $500K in private placement (June 2026) and maintains $315M cash position, ensuring runway for pipeline advancement.

Watch Out For

Severe pipeline fragmentation: 16 programs span oncology, dermatology, cardiology, psychiatry, and lifestyle interventions with no clear strategic focus, suggesting organizational confusion or mission drift.
Pipeline quality concerns: only 2 Phase 3 programs (Nailner 2 in 1, Rituximab); most programs lack active trials and phase information, indicating slow clinical progression.
Heavy cash burn: $239M net loss in FY2025 on only $271M revenue, with declining cash from $386M to $315M year-over-year despite revenue growth.
Zero active job openings reported despite public status, suggesting either minimal headcount, hiring freeze, or data quality issues.

Generated by Claude from ME Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

NCT07417579Mindfulness and Meditation-Based Relapse Prevention for Substance Use Disorders

N/A

Revascularization

Coronary Syndrome, Acute, Non-ST Elevation, High Risk Patients

N/A

Clinical Trials (1)

NCT06279663Management Tactics for Patients High Risk With Acute Coronary Syndrome Without ST Segment Elevation and Multivessel Coronary Artery Disease

N/A

Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Myalgic Encephalomyelitis

N/A

Clinical Trials (1)

NCT03254823Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

N/A

Feasibility study of music-based mobile app

Dementia

N/A

Clinical Trials (1)

NCT06140342A Music-Based Mobile App for People Living With Alzheimer's Disease and Related Dementias (ADRD)